About Careers Internship MedBlog Contact us
Medindia LOGIN REGISTER
Advertisement

Sunitinib a Promising Agent for Treatment of Renal Cell Cancer

by Medindia Content Team on June 7, 2006 at 3:41 PM
Font : A-A+

Sunitinib a Promising Agent for Treatment of Renal Cell Cancer

Sunitinib has been found to be an effective agent for treating metastatic renal cell cancer, a disease for which no effective treatment options are available so far.

There is an urgent need for more active agents for the treatment of metastatic (spread of cancer from point of origin to another part of the body) renal cell carcinoma (RCC). The 5-year survival rate for metastatic RCC is estimated to be less than 10 percent, according to background information in the article. RCC is highly resistant to chemotherapy, and only a limited subset of patients (20 percent or less) benefit from cytokine (proteins from the immune system) therapy (high-dose interleukin-2 [IL-2] and/or interferon-alfa). Overall median survival following progression after cytokine therapy is approximately 10 to 13 months, and no effective treatment is available for patients whose disease progresses after an initial response, or who do not respond to cytokine therapy.

Advertisement

A better understanding of the genetic abnormalities associated with clear-cell RCC has helped identify new targets for therapy, and subsequently the development of a new therapy, the oral medication sunitinib, which had positive results in an initial study.

Robert J. Motzer, M.D., of Memorial Sloan-Kettering Cancer Center, New York, and colleagues conducted a multicenter phase 2 trial to confirm the antitumor efficacy of sunitinib in 106 patients with metastatic clear-cell RCC whose disease was refractory (unresponsive) to 1 prior cytokine therapy.
Advertisement

Patients were enrolled between February and November 2004, with follow-up continuing until disease progression, unacceptable toxicity, or withdrawal of consent. Patients received repeated 6-week cycles of sunitinib, 50 mg per day given orally for 4 consecutive weeks followed by 2 weeks off per treatment cycle.

"The results of this trial confirm that sunitinib given once daily according to a 4 weeks on/2 weeks off schedule has substantial antitumor effects against metastatic clear-cell RCC. Of the 105 evaluable patients, 36 patients achieved partial response (34 percent), and a median progression-free survival of 8.3 months as evaluated by the independent third-party core imaging laboratory (resulting in a value considerably longer than expected in this clinical setting)," the authors write.

The most common adverse events experienced by patients were fatigue 30 (28 percent) and diarrhea 21 (20 percent).

(Source: Newswise)
Advertisement

Advertisement
News A-Z
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
What's New on Medindia
Alarming Cesarean Section Trends in India - Convenience or Compulsion of Corporate Healthcare
Quiz on Low-Calorie Diet for Diabetes
World Heart Day in 2022- Use Heart for Every Heart
View all
Recommended Reading
News Archive
Date
Category
Advertisement
News Category

Medindia Newsletters Subscribe to our Free Newsletters!
Terms & Conditions and Privacy Policy.

More News on:
Cancer and Homeopathy Vesico-Ureteric Reflux Causing UTI in Children Hydronephrosis / Antenatal Counseling Cancer Facts Cancer 

Most Popular on Medindia

Find a Doctor Find a Hospital Post-Nasal Drip Drug - Food Interactions A-Z Drug Brands in India Drug Side Effects Calculator Calculate Ideal Weight for Infants Sanatogen Drug Interaction Checker Iron Intake Calculator
This site uses cookies to deliver our services. By using our site, you acknowledge that you have read and understand our Cookie Policy, Privacy Policy, and our Terms of Use
×

Sunitinib a Promising Agent for Treatment of Renal Cell Cancer Personalised Printable Document (PDF)

Please complete this form and we'll send you a personalised information that is requested

You may use this for your own reference or forward it to your friends.

Please use the information prudently. If you are not a medical doctor please remember to consult your healthcare provider as this information is not a substitute for professional advice.

Name *

Email Address *

Country *

Areas of Interests